The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: A report from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Fortunato Morabito, C. Stelitano, S. Luminari, C. Mammi, L. Marcheselli, V. Callea, M. Gentile, G. Polimeno, F. Merli, S. Molica, P. Gobbi, F. Angrilli, M. Brugiatelli, M. Federico

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

GISL recently conducted an exhaustive survey of 1078 patients with Hodgkin's Lymphoma (HL) enrolled between 1988 and 2002 in different prospective trials. Treatment failure was observed in 82 out of 1078 patients; of these 82 patients with refractory HL, complete information was available for 72, who form the evaluable population of the present study. After the initial therapy failure, 51 patients were treated with conventional salvage chemotherapy (CC) (n=24) or high-dose chemotherapy (HDC) (n=27); 4-year overall survival (OS) was 81% in the HDC group versus 38% in the CC group (P=0.019). The remaining 21 patients had rapidly progressive disease and died. After a median follow-up of 2.8 years, the projected OS for all 72 patients is 58 and 49% at 3 and 5 years, respectively. Age

Original languageEnglish
Pages (from-to)283-288
Number of pages6
JournalBone Marrow Transplantation
Volume37
Issue number3
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Stem Cell Transplantation
Hodgkin Disease
Drug Therapy
Therapeutics
Survival
Treatment Failure
Population

Keywords

  • Autologous bone marrow transplantation
  • Conventional chemotherapy
  • Overall survival
  • Refractory Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma : A report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). / Morabito, Fortunato; Stelitano, C.; Luminari, S.; Mammi, C.; Marcheselli, L.; Callea, V.; Gentile, M.; Polimeno, G.; Merli, F.; Molica, S.; Gobbi, P.; Angrilli, F.; Brugiatelli, M.; Federico, M.

In: Bone Marrow Transplantation, Vol. 37, No. 3, 02.2006, p. 283-288.

Research output: Contribution to journalArticle

Morabito, F, Stelitano, C, Luminari, S, Mammi, C, Marcheselli, L, Callea, V, Gentile, M, Polimeno, G, Merli, F, Molica, S, Gobbi, P, Angrilli, F, Brugiatelli, M & Federico, M 2006, 'The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: A report from the Gruppo Italiano per lo Studio dei Linfomi (GISL)', Bone Marrow Transplantation, vol. 37, no. 3, pp. 283-288. https://doi.org/10.1038/sj.bmt.1705235
Morabito, Fortunato ; Stelitano, C. ; Luminari, S. ; Mammi, C. ; Marcheselli, L. ; Callea, V. ; Gentile, M. ; Polimeno, G. ; Merli, F. ; Molica, S. ; Gobbi, P. ; Angrilli, F. ; Brugiatelli, M. ; Federico, M. / The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma : A report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). In: Bone Marrow Transplantation. 2006 ; Vol. 37, No. 3. pp. 283-288.
@article{17424e50e9e44de39d8206d95e54e9f9,
title = "The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: A report from the Gruppo Italiano per lo Studio dei Linfomi (GISL)",
abstract = "GISL recently conducted an exhaustive survey of 1078 patients with Hodgkin's Lymphoma (HL) enrolled between 1988 and 2002 in different prospective trials. Treatment failure was observed in 82 out of 1078 patients; of these 82 patients with refractory HL, complete information was available for 72, who form the evaluable population of the present study. After the initial therapy failure, 51 patients were treated with conventional salvage chemotherapy (CC) (n=24) or high-dose chemotherapy (HDC) (n=27); 4-year overall survival (OS) was 81{\%} in the HDC group versus 38{\%} in the CC group (P=0.019). The remaining 21 patients had rapidly progressive disease and died. After a median follow-up of 2.8 years, the projected OS for all 72 patients is 58 and 49{\%} at 3 and 5 years, respectively. Age",
keywords = "Autologous bone marrow transplantation, Conventional chemotherapy, Overall survival, Refractory Hodgkin's lymphoma",
author = "Fortunato Morabito and C. Stelitano and S. Luminari and C. Mammi and L. Marcheselli and V. Callea and M. Gentile and G. Polimeno and F. Merli and S. Molica and P. Gobbi and F. Angrilli and M. Brugiatelli and M. Federico",
year = "2006",
month = "2",
doi = "10.1038/sj.bmt.1705235",
language = "English",
volume = "37",
pages = "283--288",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma

T2 - A report from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

AU - Morabito, Fortunato

AU - Stelitano, C.

AU - Luminari, S.

AU - Mammi, C.

AU - Marcheselli, L.

AU - Callea, V.

AU - Gentile, M.

AU - Polimeno, G.

AU - Merli, F.

AU - Molica, S.

AU - Gobbi, P.

AU - Angrilli, F.

AU - Brugiatelli, M.

AU - Federico, M.

PY - 2006/2

Y1 - 2006/2

N2 - GISL recently conducted an exhaustive survey of 1078 patients with Hodgkin's Lymphoma (HL) enrolled between 1988 and 2002 in different prospective trials. Treatment failure was observed in 82 out of 1078 patients; of these 82 patients with refractory HL, complete information was available for 72, who form the evaluable population of the present study. After the initial therapy failure, 51 patients were treated with conventional salvage chemotherapy (CC) (n=24) or high-dose chemotherapy (HDC) (n=27); 4-year overall survival (OS) was 81% in the HDC group versus 38% in the CC group (P=0.019). The remaining 21 patients had rapidly progressive disease and died. After a median follow-up of 2.8 years, the projected OS for all 72 patients is 58 and 49% at 3 and 5 years, respectively. Age

AB - GISL recently conducted an exhaustive survey of 1078 patients with Hodgkin's Lymphoma (HL) enrolled between 1988 and 2002 in different prospective trials. Treatment failure was observed in 82 out of 1078 patients; of these 82 patients with refractory HL, complete information was available for 72, who form the evaluable population of the present study. After the initial therapy failure, 51 patients were treated with conventional salvage chemotherapy (CC) (n=24) or high-dose chemotherapy (HDC) (n=27); 4-year overall survival (OS) was 81% in the HDC group versus 38% in the CC group (P=0.019). The remaining 21 patients had rapidly progressive disease and died. After a median follow-up of 2.8 years, the projected OS for all 72 patients is 58 and 49% at 3 and 5 years, respectively. Age

KW - Autologous bone marrow transplantation

KW - Conventional chemotherapy

KW - Overall survival

KW - Refractory Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=33645283388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645283388&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705235

DO - 10.1038/sj.bmt.1705235

M3 - Article

C2 - 16327815

AN - SCOPUS:33645283388

VL - 37

SP - 283

EP - 288

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -